Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

Event-Driven

<ul>
<li>On 28 May, the the U.S. Court of Appeals completely overturned the $59.4 million trade secret verdict that Insulet had previously won against its South Korean rival, Eoflow (294090 KS). </li>
<li>This is likely to have a major positive impact on Eoflow and negatively impact Insulet, which earned $781.8 million from sales of the Omnipod, its flagship product, in 2025. </li>
<li>Eoflow's shares trading has been temporarily suspended. Once it does start trading again, its share price is likely to APPRECIATE SEVERAL TIMES its current value.</li>
</ul>


On 28 May, the the U.S. Court of Appeals completely overturned the $59.4 million trade secret verdict that Insulet had previously won against its South Korean rival, Eoflow (294090 KS). 
This is likely to have a major positive impact on Eoflow and negatively impact Insulet, which earned $781.8 million from sales of the Omnipod, its flagship product, in 2025. 
Eoflow's shares trading has been temporarily suspended. Once it does start trading again, its share price is likely to APPRECIATE SEVERAL TIMES its current value.


Eoflow: Stayin' Alive [U.S. Court of Appeals Overturns $59.4 Mn Trade Secret Verdict Vs Insulet]

Smartkarma's AI Co-Pilot, Smartkarma

αSK

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/eoflow-co-ltd">Eoflow</a> is a high-risk, pre-profitable medical device company whose primary product, the EOPatch wearable insulin pump, faces intense competition and significant legal challenges that threaten its viability.</li>
 <li>The company's financial performance is characterized by substantial and consistent net losses, negative margins, and negative cash flow, with its ability to continue as a going concern clouded by a major patent infringement lawsuit.</li>
 <li>A planned acquisition by Medtronic, which would have provided a crucial global distribution network and financial stability, was terminated in late 2023, leaving <a href="https://smartkarma.com/entities/eoflow-co-ltd">Eoflow</a> in a precarious strategic position.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Eoflow is a high-risk, pre-profitable medical device company whose primary product, the EOPatch wearable insulin pump, faces intense competition and significant legal challenges that threaten its viability.
  The company's financial performance is characterized by substantial and consistent net losses, negative margins, and negative cash flow, with its ability to continue as a going concern clouded by a major patent infringement lawsuit.
  A planned acquisition by Medtronic, which would have provided a crucial global distribution network and financial stability, was terminated in late 2023, leaving Eoflow in a precarious strategic position.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

<ul>
<li>In this insight, we discuss the additional financing requirements, changed shareholding structure, and the next steps for Eoflow. </li>
<li>Eoflow is one of the best performing stocks in the Korean stock market in the past one month as its shares have soared 249% in this period.</li>
<li>The details of the oral argument (Insulet vs Eoflow) at the U.S. Appellate Court suggest that the U.S. Appellate Court may rule in favor of Eoflow.</li>
</ul>


In this insight, we discuss the additional financing requirements, changed shareholding structure, and the next steps for Eoflow. 
Eoflow is one of the best performing stocks in the Korean stock market in the past one month as its shares have soared 249% in this period.
The details of the oral argument (Insulet vs Eoflow) at the U.S. Appellate Court suggest that the U.S. Appellate Court may rule in favor of Eoflow.


Eoflow: Financing Requirements, Changing Shareholding Structure, and the Next Steps

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

<ul>
<li>I tally 50 - mostly firm, mostly Asia-Pac - transactions currently being discussed and analysed on Smartkarma. Inside is a timetable of upcoming key events for each deal.</li>
<li>Three new deals discussed this week: <a href="https://www.smartkarma.com/entities/fancl-corp" target="_blank" data-smartkarma-citation="entities:15862:1" rel="noopener">Fancl (4921 JP)</a>'s Tender offer, <a href="https://www.smartkarma.com/entities/a8-new-media-group-ltd" target="_blank" data-smartkarma-citation="entities:3444:1" rel="noopener">A8 New Media (800 HK)</a>'s Scheme, and <a href="https://www.smartkarma.com/entities/jeisys-medical-inc" target="_blank" data-smartkarma-citation="entities:36766:1" rel="noopener">Jeisys Medical (287410 KS)</a>'s delisting offer. Bain also approached <a href="https://www.smartkarma.com/entities/bapcor-ltd" target="_blank" data-smartkarma-citation="entities:8433:1" rel="noopener">Bapcor (BAP AU)</a>.</li>
<li>Key updates took place on: <a href="https://www.smartkarma.com/entities/sigma-healthcare-ltd" target="_blank" data-smartkarma-citation="entities:15966:1" rel="noopener">Sigma Healthcare (SIG AU)</a>, <a href="https://www.smartkarma.com/entities/alumina-ltd" target="_blank" data-smartkarma-citation="entities:939:1" rel="noopener">Alumina (AWC AU)</a>, <a href="https://www.smartkarma.com/entities/greatview-aseptic-packaging" target="_blank" data-smartkarma-citation="entities:10802:1" rel="noopener">Greatview Aseptic Packaging (468 HK)</a>, <a href="https://www.smartkarma.com/entities/helios-techno-holding-co-ltd" target="_blank" data-smartkarma-citation="entities:13934:1" rel="noopener">Helios Techno (6927 JP)</a>, and <a href="https://www.smartkarma.com/entities/tatsuta-electric-wire-cable-co-ltd" target="_blank" data-smartkarma-citation="entities:12509:1" rel="noopener">Tatsuta Electric Wire &amp; Cable (5809 JP)</a>.</li>
</ul>


I tally 50 - mostly firm, mostly Asia-Pac - transactions currently being discussed and analysed on Smartkarma. Inside is a timetable of upcoming key events for each deal.
Three new deals discussed this week: Fancl (4921 JP)'s Tender offer, A8 New Media (800 HK)'s Scheme, and Jeisys Medical (287410 KS)'s delisting offer. Bain also approached Bapcor (BAP AU).
Key updates took place on: Sigma Healthcare (SIG AU), Alumina (AWC AU), Greatview Aseptic Packaging (468 HK), Helios Techno (6927 JP), and Tatsuta Electric Wire &amp; Cable (5809 JP).


(Mostly) Asia-Pac M&A: Fancl, Jeisys Medical, A8 New Media, Bapcor, Helios Techno,Tatsuta Electric

<ul>
<li>This insight provides a detailed analysis of Eoflow's appellant brief (released on 4 December) on Insulet Corp (PODD US)'s lawsuit. </li>
<li>We provide the following three major reasons why we believe Eoflow will win versus Insulet in this lawsuit.</li>
<li>One of the most important arguments on Eoflow's appellant brief is the DTSA three years statute of limitations.</li>
</ul>


This insight provides a detailed analysis of Eoflow's appellant brief (released on 4 December) on Insulet Corp (PODD US)'s lawsuit. 
We provide the following three major reasons why we believe Eoflow will win versus Insulet in this lawsuit.
One of the most important arguments on Eoflow's appellant brief is the DTSA three years statute of limitations.


South Korea

Eoflow Co.,Ltd. develops and sells medical devices. The Company produces and sells wearable disposable insulin pumps and other products. Eoflow markets its products throughout Korea.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Eoflow (294090 KS)

Eoflow: Stayin' Alive [U.S. Court of Appeals Overturns $59.4 Mn Trade Secret Verdict Vs Insulet]

On 28 May, the the U.S. Court of Appeals completely overturned the $59.4 million trade secret verdict that Insulet had previously won against its...

Douglas Kim

Primer: Eoflow (294090 KS) - Apr 2026

Eoflow is a high-risk, pre-profitable medical device company whose primary product, the EOPatch wearable insulin pump, faces intense...

αSK

Eoflow: Financing Requirements, Changing Shareholding Structure, and the Next Steps

Eoflow's shares surged by 30% to 15,080 won today. Eoflow announced today that the U.S. District Court in Massachusetts had revoked the injunction...

Douglas Kim

(Mostly) Asia-Pac M&A: Fancl, Jeisys Medical, A8 New Media, Bapcor, Helios Techno,Tatsuta Electric

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

David Blennerhassett

Eoflow Vs Insulet: Round II

This insight provides an analysis of Eoflow's appellant brief on Insulet's lawsuit. We provide the three major reasons why we believe Eoflow will...

Douglas Kim

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)